Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab.
Lin DI, Quintanilha JCF, Danziger N, Lang L, Levitan D, Hayne C, Hiemenz MC, Smith DL, Albacker LA, Leibowitz J, Mata DA, Decker B, Lakis S, Patel NR, Graf RP, Elvin JA, Ross JS, Pattani V, Huang RSP, Wehn AK.
Lin DI, et al. Among authors: quintanilha jcf.
NPJ Precis Oncol. 2024 Sep 14;8(1):204. doi: 10.1038/s41698-024-00679-7.
NPJ Precis Oncol. 2024.
PMID: 39277692
Free PMC article.